2-(2'-anilinyl)-2-benz-5-N-oxazole | 95308-00-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(2'-anilinyl)-2-benz-5-N-oxazole
• 英文别名: 2-(oxazolo[4,5-b]pyridin-2-yl)aniline；2-([1,3]oxazolo[4,5-b]pyridin-2-yl)aniline
• CAS: 95308-00-2
• 化学式: C₁₂H₉N₃O
• 分子量: 211.223
• InChiKey: MTNVHWFTXUNFMQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  64.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3,4-二甲氧基苯甲酰氯 、 2-(2'-anilinyl)-2-benz-5-N-oxazole 在 吡啶 作用下， 以 二氯甲烷 为溶剂， 反应 0.17h， 生成 3,4-dimethoxy-N-[2-([1,3]oxazolo[4,5-b]pyridin-2-yl)phenyl]benzamide
  参考文献：
  名称：

  Discovery of oxazolo[4,5-b]pyridines and related heterocyclic analogs as novel SIRT1 activators

  摘要：

  SIRT1 is an NAD(+)-dependent protein deacetylase that appears to produce beneficial effects on metabolic parameters such as glucose and insulin homeostasis. Activation of SIRT1 by resveratrol ( 1) has been shown to modulate insulin resistance, increase mitochondrial content and prolong survival in lower organisms and in mice on a high fat diet. Herein, we describe the identification and SAR of a series of oxazolo[4,5-b]pyridines as novel small molecule activators of SIRT1 which are structurally unrelated to and more potent than resveratrol. (C) 2009 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2008.11.106
• 作为产物：
  描述：

  2-氨基-3-羟基吡啶 、 靛红酸酐 在 zinc(II) chloride 作用下， 以 氯苯 为溶剂， 以45%的产率得到2-(2'-anilinyl)-2-benz-5-N-oxazole
  参考文献：
  名称：

  恶唑啉化学部分III。[2-（2'-苯胺基）-2-恶唑啉]及一些相关化合物的合成与表征

  摘要：

  报道了一系列手性和非手性2-（氨基苯基）-2-恶唑啉及一些相关化合物的合成与表征。所有衍生物均是通过一步法生产的，其中涉及对等酸酐的处理（即[2 H ] -3、1-苯并恶嗪-[1 H -2,4-二酮：1 ]或其5-氯类似物并略有过量的适当氨基醇。在大多数情况下，在高沸点芳烃溶剂（PhCl或PhMe）中，在回流温度下，无水ZnCl 2被证明是该反应的有效路易斯酸催化剂。使用rac -2-氨基-1-丁醇，（S）-苯基甘醇，2-甲基-2-氨基-1-丙醇和（1S，2R）或（1R，2S） -顺式- 1 -氨基-2-茚满醇; 收率从85％到22％。使用氨基醇，例如2-乙醇胺，（±）-2-氨基-1-苯基-1-丙醇或3-氨基-1-丙醇（得到相应的4,5-二氢-1,3-恶嗪）导致产量不佳。使用其他路易斯酸催化剂（硅酸，Cd（acac）2 ·2H 2 O，CuCl 2 ·2H 2 O，InCl 3）或更高的温

  DOI：

  10.1002/jhet.5570400316

文献信息

• <i>N</i>-aryl 2-aryloxyacetamides as a new class of fatty acid amide hydrolase (FAAH) inhibitors
  作者：Naresh Sunduru、Mona Svensson、Mariateresa Cipriano、Sania Marwaha、C. David Andersson、Richard Svensson、Christopher J. Fowler、Mikael Elofsson

  DOI：10.1080/14756366.2016.1265520

  日期：2017.1.1

  Fatty acid amide hydrolase (FAAH) is a promising target for the development of drugs to treat neurological diseases. In search of new FAAH inhibitors, we identified 2-(4-cyclohexylphenoxy)-N-(3-(oxazolo[4,5-b]pyridin-2-yl)phenyl)acetamide, 4g, with an IC50 of 2.6 µM as a chemical starting point for the development of potent FAAH inhibitors. Preliminary hit-to-lead optimisation resulted in 2-(4-phe

  脂肪酸酰胺水解酶（FAAH）是开发用于治疗神经系统疾病的药物的有希望的目标。为了寻找新的FAAH抑制剂，我们确定了2g 2-（4-环己基苯氧基）-N-（3-（恶唑并[4,5-b]吡啶-2-基）苯基）乙酰胺，IC50为2.6 µM，开发有效的FAAH抑制剂的化学起点。初步的逐线优化得到2-i-（4-phenylphenoxy）-N-（3-（oxazolo [4,5-b] pyridin-2-yl）phenyl）乙酰胺4i，IC50为0.35 µM。
• Sirtuin modulating compounds
  申请人：Nunes J. Joseph

  公开号：US20070037809A1

  公开（公告）日：2007-02-15

  Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benfit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本文提供了新型的sirtuin调节化合物及其使用方法。这些sirtuin调节化合物可用于增加细胞寿命，并治疗和/或预防各种疾病和疾病，包括与衰老或应激有关的疾病或疾病，糖尿病，肥胖症，神经退行性疾病，心血管疾病，血液凝块性疾病，炎症，癌症和/或红斑病，以及需要增加线粒体活性的疾病或疾病。还提供了包含sirtuin调节化合物和另一种治疗剂的组合物。
• SIRTUIN MODULATING COMPOUNDS
  申请人：Nunes Joseph J.

  公开号：US20120197013A1

  公开（公告）日：2012-08-02

  Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本文提供了一种新颖的调节沉默信息调节因子（sirtuin）的化合物及其使用方法。这些调节sirtuin的化合物可用于延长细胞寿命，并用于治疗和/或预防多种疾病和障碍，包括与衰老或应激有关的疾病或障碍、糖尿病、肥胖症、神经退行性疾病、心血管疾病、血液凝结障碍、炎症、癌症和/或潮红，以及需要增加线粒体活性的疾病或障碍。还提供了包含sirtuin调节化合物与另一种治疗药物组合的组合物。
• Imidazo[2,1-b]thiazole derivatives as sirtuin modulators
  申请人：Sirtris Pharmaceuticals, Inc.

  公开号：EP2388263A1

  公开（公告）日：2011-11-23

  Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benfit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本文提供了新型sirtuin调节化合物及其使用方法。sirtuin调节化合物可用于延长细胞寿命，治疗和/或预防多种疾病和失调，包括与衰老或压力、糖尿病、肥胖症、神经退行性疾病、心血管疾病、凝血障碍、炎症、癌症和/或潮红有关的疾病或失调，以及可从线粒体活性增强中获益的疾病或失调。此外，还提供了由sirtuin调节化合物与另一种治疗剂组合而成的组合物。
• Thiazolopyridine derivatives as sirtuin-modulators
  申请人：Sirtris Pharmaceuticals, Inc.

  公开号：EP2468752A1

  公开（公告）日：2012-06-27

  Provided herein are novel sirtuin-modulating compounds (XII) and (XIII). The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本文提供的是新型 sirtuin 调节化合物 (XII) 和 (XIII)。sirtuin调节化合物可用于延长细胞寿命，治疗和/或预防多种疾病和失调，包括与衰老或压力、糖尿病、肥胖症、神经退行性疾病、心血管疾病、凝血障碍、炎症、癌症和/或潮红有关的疾病或失调，以及可从线粒体活性增强中获益的疾病或失调。此外，还提供了由sirtuin调节化合物与另一种治疗剂组合而成的组合物。